Pyxis Oncology Q2 loss widens on increased administrative costs
PYXS•Expense drivers and analyst view
Research and development expenses declined, mainly due to lower manufacturing costs, while general and administrative expenses increased because of higher severance and stock-based compensation.
The current average analyst rating on the shares is buy, with 9 strong buy or buy ratings, 1 hold, and no sell or strong sell ratings. The median 12-month price target is $7.00, about 120.1% above the August 12 closing price of $3.18.
Q2 loss widens as operating expenses rise
Pyxis Oncology Inc said its second-quarter net loss widened year over year as operating expenses rose.
The US cancer therapeutics developer reported a Q2 loss per share of $0.40 and a net loss of $25.35 million. Income from operations was -$25.99 million and operating expenses were $25.99 million.
Private placement extends cash runway into Q2 2027
The company completed a , extending its cash runway into .
